In vivo relevance of CD30 in atopic dermatitis.
CD30 expression was evaluated by immunohistochemistry in lesional skin biopsies of eight patients with active atopic dermatitis (AD) and three patients with allergic contact (nickel-induced) dermatitis (ACD). CD30 expression was also assessed in a large panel of CD4+ and CD8+ T-cell clones generated from the skin biopsies of four patients with AD. Finally, the levels of soluble CD30 (sCD30) were measured in the serum of 41 patients with AD, 19 patients with ACD, and 60 healthy controls. In all specimens of lesional AD skin, where the great majority of infiltrating cells were CD4+ T cells, remarkable numbers of cells were CD30+, whereas virtually no CD30+ cells were found in the skin of patients with ACD. In CD4+ T-cell clones generated from the lesional AD skin, most of which produced both interleukin (IL)-4 and interferon-gamma (IFN-gamma) (Th0-like cells) or IL-4 and IL-5, but not IFN-gamma (Th2-like cells), CD30 expression directly correlated with the ability to produce IL-4 and IL-5, but was inversely related to IFN-gamma production. High levels of sCD30 (correlated with disease activity: r = 0.618) were detected in the serum of most AD patients, whereas there was no increase of sCD30 levels in the serum of patients with ACD. These data support the view that Th0/Th2-type responses predominate in the skin of patients with AD and suggest that the presence of CD30+ T cells in tissues and/or increased levels of sCD30 in biologic fluids are indicative of Th2-dominated responses.
Caproni
M
M
Department of Dermatology, University of Florence, Italy.
Bianchi
B
B
D'Elios
M M
MM
De Carli
M
M
Amedei
A
A
Fabbri
P
P
D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000737:chemistry / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry / Q000378:metabolism; D002999:Clone Cells / Q000737:chemistry / Q000378:metabolism; D017449:Dermatitis, Allergic Contact / Q000209:etiology; D003876:Dermatitis, Atopic / Q000276:immunology*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis / Q000096:biosynthesis; D015847:Interleukin-4 / Q000032:analysis / Q000096:biosynthesis; D015848:Interleukin-5 / Q000032:analysis / Q000096:biosynthesis; D017730:Ki-1 Antigen / Q000032:analysis* / Q000096:biosynthesis / Q000097:blood; D008233:Lymphotoxin-alpha / Q000032:analysis / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009532:Nickel / Q000009:adverse effects; D012867:Skin / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000737:chemistry / Q000378:metabolism
D015848:Interleukin-5; D017730:Ki-1 Antigen; D008233:Lymphotoxin-alpha; D015847:Interleukin-4; D009532:Nickel; D007371:Interferon-gamma